VREX · Varex Imaging

The thesis

Varex Imaging Corporation remains a deal-completion case with capped upside: Teledyne Technologies has agreed to pay $18.90 per share in cash, and the US and UK reviews ending 19 November 2026 and 18 November 2026 decide whether completion in early 2027 stays on track. The shares closed at $18.45 on 10 November 2026 (adjusted daily closes), $0.45 under the cash price.

Nothing in company news since the 28 October 2026 stockholder approval changes the terms. The only new item is a 31 October 2026 notice of a Bundeskartellamt (German competition authority) merger-control filing covering Teledyne and Varex, which starts the German review that the proxy listed among required foreign clearances.

The narrative is saturated: the price has tracked the cash offer since the 10 August 2026 announcement, and the shares are down 0.3% over three months, against a 52-week high of $18.58. The odds of beating the S&P 500 over the next three months are weak, because the most the shares can gain is the remaining gap to $18.90, and payment probably falls near or after the end of that window.

Bullish and bearish views on Varex Imaging Corporation

The bull case on Varex Imaging Corporation (VREX), in brief: stockholder condition is met. The bear case: US timetable has already slipped once.

Bull case

• Stockholder condition is met. Holders approved the merger agreement on 28 October 2026. MarketBeat reported about 32.53 million shares, roughly 77% of those eligible, were represented in the preliminary count.
• No financing condition. The 10 August 2026 merger agreement pays a fixed cash price and does not depend on Teledyne raising money, per the 8-K.
• Review clocks end inside 30 days. MLex reported on 22 October 2026, citing a Varex filing, that the UK National Security and Investment Act review runs to 18 November 2026 and the US Hart-Scott-Rodino (HSR) antitrust waiting period expires at 11:59 p.m. Eastern on 19 November 2026. Both finish this month unless a regulator extends them.
• Break fee and long runway. The agreement carries a $25.3 million company termination fee and an outside date of 10 May 2027, extendable to 10 August 2027, per the definitive proxy dated 21 September 2026.
• Buyer frames the deal as complementary. Coverage of the announcement describes Teledyne as acquiring a supplier to the imaging industry rather than a competitor, which bears on the US antitrust review. That is press analysis, not a regulator's finding.

Bear case

• US timetable has already slipped once. The proxy dated HSR expiry to 16 October 2026, and MLex on 22 October 2026 put it at 19 November 2026. A second request on overlap in X-ray detectors and imaging components would add months.
• Foreign reviews are still open. The preliminary proxy of 8 September 2026 lists merger control in Austria, China, Germany, Japan, Saudi Arabia and Ukraine. The German filing was only noticed on 31 October 2026, and a slow review in China would push payment past early 2027.
• Stockholder litigation. Varex's 8-K of 22 October 2026 disclosed two stockholder lawsuits alleging the proxy was misleading and 13 demand letters. The company called the claims meritless and made supplemental disclosures.
• Weak standalone cash generation. Nine-month fiscal 2026 operating cash flow was $3.4 million, against $33.8 million a year earlier, per the 10-Q for the quarter ended 3 July 2026. If the deal failed, the shares would rest on those results.
• Downside is far larger than upside. A termination would send the shares back toward the pre-announcement price, well below $18.45, while completion adds only the gap to $18.90.

Price setup

The adjusted close on 10 November 2026 was $18.45, 0.7% below the 52-week high of $18.58. The 14-day Relative Strength Index was 54.8, a neutral reading. The shares have moved in a narrow band under the $18.90 cash price since 10 August 2026, which is what a fixed-price deal produces.

The price carries a small discount to $18.90. That discount reflects the time to payment and the chance of delay or failure.

Crowding evidence is thin on the buying side. No filings were reported in the last 30 days, and the only dated attention items are the stockholder vote and the regulatory filings. Varex cancelled its fiscal third-quarter earnings call because of the pending deal.

Catalysts ahead

• 18 November 2026: End of the UK National Security and Investment Act review period. Clearance removes the UK condition. An extension would signal a longer path to completion.
• 19 November 2026: HSR antitrust waiting period expires at 11:59 p.m. ET. Expiry without a second request satisfies the US antitrust condition. A second request would push completion out by months.
• ~30 November 2026 (est.): End of a standard one-month first-phase German merger-control review, from the 31 October 2026 filing notice. German clearance is one of the listed foreign conditions. A longer review would delay completion.
• ~December 2026 (est.): Fiscal Q4 and full-year 2026 results or annual report on Form 10-K. This is the last standalone view of operations and shows what the shares would rest on if the deal failed.

What would change the view

A daily close above $20.23, 10% above the last close (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.

What it trades with

The shares trade on the deal spread, not on medtech or imaging-sector moves, so their link to the S&P 500 is weak while the deal stands. Teledyne's own share price does not affect the cash payment. A broad credit or market shock matters mainly if it changes regulators' timing or Teledyne's willingness to close. If the deal failed, the shares would revert to trading with other small-cap X-ray component suppliers and with the standalone results.